Effector Therapeutics Inc (EFTR) said after close Monday that it lost $3.42 per share in quarter four 2023. The company reported $0.00 in revenue
In the same quarter a year ago, the company lost $5.5 per share on revenue of $674 thousand.
The stock is down 11.74% to $11.97 after the report.
Effector Therapeutics Inc's revenues declined at a faster pace than earnings.
Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.
InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.
Effector Therapeutics Inc has performed a little above average during the past few months. Before the report, Effector Therapeutics Inc received a Long-Term Technical Rank by InvestorsObserver of 66, putting it in the top half of stocks. The firm set a 52-week high on June 6, 2023 at $37 and set a 52-week low on March 30, 2023 at $8.45.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.